The ki:e SB-C is based on speech recordings from two gold standard cognitive tests (Semantic Verbal Fluency and Rey Auditory Verbal Learning task) that take 10-15 minutes to perform. More than 120 features are automatically extracted from the recordings and combined into a cognitive composite and three sub-scales measuring executive function, episodic memory, and processing speed.
It has applicability to the following disease areas:
The SB-C has been validated in multiple studies to show relation to existing measures (i.e., MMSE, CDR), its test-retest reliability and its ability to detect clinically meaningful differences. The full validation evidence is compiled in an evidence dossier according to scientific standards (DIME, Walton 2020).
Strong correlation of the ki:e SB-C biomarker with MMSE total score.
Significant group differences between Dementia, MCI and HC.
SB-C can be used for multiple different applications in and around trials. It’s a valid measure to track cognition and can be used as a decentralized assessment tool. SB-C can also be used to screen participants for Mild cognitive impairment (MCI), e.g., as a pre-screener for trial recruitment.
We’re looking forward to working with you! SB-C is deployed via our Mili platform into clinical studies and trials. If you are interested in deploying it in your study, please reach out to us.
Academic groups wanting to use the technology can partner with us to receive reduced licensing costs.
Your message (optional)
I agree that my details from the contact form are collected and processed to answer my enquiry. The data will be stored for 10 years or deleted upon request.
Note: You can revoke your consent for the future at any time by sending an email to [email protected] Detailed information on the handling of user data can be found in our data protection statement.